Women of childbearing potential must have a negative beta-human chorionic gonadotropin (B-HCG) pregnancy test documented within 14 days prior to registration
Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin pregnancy test within 7 days prior to Day 1.
Negative pregnancy test (urine or serum beta human chorionic gonadotropin [b-hCG]) at Screening for women of child bearing potential who are sexually active
Negative urine ?-human chorionic gonadotropin (?-HCG) pregnancy test for fertile women at screening and confirmed by serum pregnancy test in the 48 hours prior to OPN-305 administration
Serum creatinine ?1.5 mg/dL or a measured creatinine clearance ?60 mL/min; and Negative serum ? hCG (human chorionic gonadotropin) test in women of childbearing potential (defined as women ?50 years of age, or >50 years of age with a history of amenorrhea for ?12 months prior to study entry).
Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within 7 days prior to the first dose of brentuximab vedotin and must agree to use an effective contraception method during the study and for 30 days following the last dose of study drug; females of non-childbearing potential are those who are post-menopausal for more than 1 year or who have had a bilateral tubal ligation or hysterectomy
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of child-bearing potential
Women of childbearing potential, or men who are able to father a child, unwilling to use a medically acceptable method of contraception during the trial; pregnant women are excluded from this study; breastfeeding is not allowed during the course of the study; female patients must have a negative pregnancy test (human chorionic gonadotropin beta subunit [B-HCG] test in urine or serum) prior to commencing study treatment
Have a negative beta-human chorionic gonadotropin (?-hCG) pregnancy test at time of study entry and within 14 days prior to planned first dose of investigational product, and
Adolescent women/young women of childbearing potential must have a negative highly sensitive serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at Screening before enrollment/randomization. Adolescent/young women who are pregnant or breastfeeding are ineligible for this study
Female of childbearing potential must have a negative serum beta-human chorionic gonadotropin (HCG) pregnancy test result within 3 days of first study dose; female patients who are surgically sterilized or who are > 45 years old and have not experienced menses for > 2 years may have beta-HCG pregnancy test waived
Patients who are women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented =< 7 days prior to registration
Women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening
PART I: Negative serum beta human chorionic gonadotropin (HCG) if female and of childbearing potential
PART II: Negative serum beta HCG if of childbearing potential
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential
Pregnancy (absence to be confirmed by beta-human chorionic gonadotropin test in women of child-bearing potential) or lactation
Negative serum beta-human chorionic gonadotropin (HCG) in females, and agreement to the use of effective contraception in males and females of childbearing potential, IS REQUIRED
Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within 14 days prior to registration
Positive urine pregnancy test (women of child bearing potential only) (QuickVue One Step human chorionic gonadotropin [hCG])
Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin or urine pregnancy test at screening
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening, within 24 hours of the first dose of anti-OX40 antibody, and every four weeks while on study treatment; women who are pregnant or breastfeeding are ineligible for this study
Women of childbearing potential must have a negative pregnancy test at screening and prior to the first dose of study drug using a highly sensitive pregnancy test either serum (Beta human chorionic gonadotropin [beta-hCG]) or urine
Female patients of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [hCG]) within 2 weeks of protocol entry if the patient is unsure of their pregnancy status. Patient signature declaring that they are not pregnant on the informed consent for treatment that is used in the Department of Radiation Oncology is also an acceptable substitution for a serum pregnancy test.
A woman of childbearing potential who is sexually active must have a negative pregnancy test (beta human chorionic gonadotropin [beta hCG]) at Screening (urine or serum)
Females of childbearing potential must have a negative beta human chorionic gonadotropin (?-hCG) pregnancy test result within 7 days prior to the first dose of study drug. Females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy.
Negative serum beta-human chorionic gonadotropin (hCG) pregnancy test within 72 hours of day 1 of induction chemotherapy in women of child-bearing potential
Female patients of childbearing potential must have a negative serum beta?human chorionic gonadotrophin (?-hCG) pregnancy test at screening and negative urine pregnancy test at Cycle 1 Day 1 prior to the first dose of study drug.
Negative beta human chorionic gonadotropin (HCG) in woman with child-bearing potential
Female subjects of childbearing potential must have a negative urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at time of screening and within 14 days prior to planned first dose of ribociclib
Female subjects of childbearing potential should have a negative urine or serum pregnancy test beta human chorionic gonadotropin (beta-hCG) within 72 hours prior to receiving the first dose of study medication
Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within 14 days prior to registration; women of childbearing potential must not be pregnant, must not be breast-feeding, and must practice adequate contraception for the duration of the study, and for 30 days after the last dose of study medication
Negative beta-human chorionic gonadotropin (hCG) pregnancy test for female patients of child-bearing potential =< 7 days before starting neratinib therapy
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study
Negative urine or serum beta-human chorionic gonadotropin (BHCG) for women of childbearing potential only (within 7 days of registration)
For patients of childbearing potential, non-pregnant state, confirmed by negative serum or urine beta-human chorionic gonadotropin (HCG) within (7) days of planned radiation treatment
Pregnancy or breast-feeding; women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test result within 14 days before the first dose of WT1-specific T cell infusion; woman of non-childbearing potential will be defined as being postmenopausal greater than one year or who have had a bilateral tubal ligation or hysterectomy; all recipients of WT1-specific T cells will be counseled to use effective birth control during participation in this study and for 12 months after the last T cell infusion
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study
Negative urine beta-human chorionic gonadotropin (B-HCG) in women of child-bearing potential within 7 days prior to start of treatment
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening and must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Negative beta human chorionic gonadotropin (HCG) in woman with child-bearing potential
Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (b-hCG) pregnancy test result within 24 hours prior to the first dose of treatment and must agree to use an effective contraception method during the study and for 23 weeks after the last dose of the study drug; females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy
Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within 24 hours prior to the first dose of treatment and must agree to use an effective contraception method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drugs; females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy
Females must not be pregnant (negative urine or serum human chorionic gonadotropin test within 72 hours of study start)
Negative serum or urine beta-human chorionic gonadotropin (beta-HCG) test (female of childbearing potential only), to be performed locally within the screening period
Negative serum or urine beta-human chorionic gonadotropin (B-HCG) test (female patient of childbearing potential* only), to be performed locally within the screening period
Women of child-bearing potential (WOCBP) must have a negative pregnancy test within 14 days of the first administration of study treatment; urine human chorionic gonadotropin (HCG) is an acceptable pregnancy assessment
Female patients of childbearing potential must have a negative serum pregnancy test (beta-human chorionic gonadotropin [hCG]) within 2 weeks of protocol entry
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study
DONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test within three weeks of mobilization
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for female patients of childbearing potential
All post-menarchal females must have a negative serum beta-human chorionic gonadotropin (beta HCG); sexually active patients of childbearing potential must agree to use an effective method of contraception during the study and for at least 6 months after
Patients may not be pregnant or breast feeding; females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within 14 days prior to the first dose of S-equol
Negative serum or urine pregnancy test beta-human chorionic gonadotropin (beta hCG) within 2 weeks prior to receiving the first dose of study medication for women of childbearing age
Negative pregnancy test (beta [B]-human chorionic gonadotropin [HCG]) within 7 days prior to registration for women of childbearing potential
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of child-bearing potential within one week prior to enrollment
Negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening for patients of childbearing potential
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study
Women of childbearing potential must have a negative beta (B)-human chorionic gonadotropin (HCG) pregnancy test documented within 7 days prior to registration
Female patients with reproductive potential who do not have a negative urine or blood beta-human chorionic gonadotropin (beta HCG) pregnancy test at screening
Negative serum beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) (to be performed within 7 days prior to start of study treatment)
Female patients of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [BhCG]) within 2 weeks of protocol entry
Females of childbearing potential (> 7 years old [yo]) must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test prior to initiation of cytoreductive therapy; sexually active patients will be informed of the risk of not using adequate contraception
Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within 14 days prior to treatment
Women must not be pregnant or lactating; women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) serum pregnancy test and agree to refrain from breast-feeding; patients of childbearing potential agree to use an effective form of contraception during chemotherapy and for 90 days following the last chemotherapy treatment
Negative serum or urine beta-human chorionic gonadotropin (b-hCG) pregnancy test at screening for patients of childbearing potential
DONOR: Not be pregnant as defined by negative serum (beta human chorionic gonadotropin [beta HCG]) pregnancy test in females of childbearing potential (non-childbearing potential defined as premenarchal, previous surgical sterilization, or postmenopausal for > 12 months)
Women of childbearing age must have a negative serum pregnancy test (beta-human chorionic gonadotropin) within 72 hours prior to initiating the conditioning regimen and be willing to not become pregnant by using effective contraception while undergoing treatment and for at least 3 months after the last dose of azacitidine
Pregnancy or breast-feeding; women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test result within 14 days before the first dose of WT1-specific T cell infusion; woman of non-childbearing potential will be defined as being postmenopausal greater than one year or who have had a bilateral tubal ligation or hysterectomy; all recipients of WT1-specific T cells will be counseled to use effective birth control during participation in this study and for 12 months after the last T cell infusion
DLI DONOR: Females of childbearing potential should have a negative serum beta-human chorionic gonadotropin (HCG) test within 1 week of beginning apheresis
Female patients of childbearing age will be excluded if they are pregnant as assessed by serum beta-human chorionic gonadotropin (b-HCG) or urine pregnancy test; a serum b-HCG test or urine pregnancy test will be performed no greater than 14 days prior to study registration
Female patient of childbearing potential must have a negative serum or urine pregnancy test beta-human chorionic gonadotropin (hCG) within 72 hours prior to receiving the first dose of study medication and agree to the use of effective methods of contraception while on study
Female patients of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [B HCG]) within 72 hours of receiving the first dose of rituximab
Women of childbearing potential must have a negative beta-human chorionic gonadotropin (B-HCG) pregnancy test documented within 7 days prior to taking the first dose of study medications
Women of childbearing potential (WOCBP) must have a negative serum pregnancy test (?-human chorionic gonadotropin) within 7 days prior to randomization.
For female patients of childbearing potential (i.e. have had a menstrual period within the past 12 months): a positive serum pregnancy test (?-human chorionic gonadotropin) within 7 days prior to enrollment.
and, have a negative serum pregnancy test at Screening, (Note: Subjects with elevated serum beta human chorionic gonadotropin (?hCG) and a demonstrated non-pregnant status through additional testing are eligible), and
A woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) pregnancy test at Screening and a negative urine pregnancy test prior to the first dose of study drug
Negative serum pregnancy test (serum HCG) within 7 days of study treatment if female and of childbearing potential (non-childbearing is defined as greater than one year post-menopausal surgically sterilized). Since beta-HCG may be falsely elevated as a result of malignancy, women of child-bearing potential who have an elevated serum beta-HCG level are eligible for enrollment if they have two Transvaginal Ultrasound (TVUS) scans one week apart along with serial beta-HCG levels two weeks apart that are inconsistent with pregnancy and a Gynecology consult to ensure that the beta- HCG level was at a value high enough to see pregnancy with TVUS.
Not pregnant based on a negative result on a serum human chorionic gonadotropin (HCG) test at screening Visit 1 and a negative urine pregnancy test prevaccination at Visit 2 (and at subsequent vaccination visits);
Negative serum beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) performed locally within 72 hours (hrs) prior to first dose
All post-menarchal females must have a negative beta-HCG
Negative beta human chorionic gonadotropin (HCG) in woman with child-bearing potential
FOCBP must have a negative pregnancy test (beta-human chorionic gonadotropin [HCG] test in urine or serum) within 7 days prior to registration on study (Note: The test will have to be repeated if cycle 1 day1 is more than 3 days from registration)
Female subjects of childbearing potential must have a negative urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at time of screening
Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (B-hCG) pregnancy test result within 14 days prior to the first dose of imipramine
Negative serum or urine beta-human chorionic gonadotropin (HcG) test (female patient of childbearing potential only) performed within 72 hours of prior to first study dose
Pregnancy test (urine or serum beta-human chorionic gonadotropin [HCG]) done within 72 hours before randomization must be negative (for women of childbearing potential only); if urine pregnancy results are positive or cannot be confirmed as negative, a serum pregnancy test will be required
A woman of childbearing potential must have a negative highly sensitive serum (beta human chorionic gonadotropin [b-hCG]) or urine test prior to the first dose of study drug
DONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test within two weeks of apheresis
Women of childbearing potential must have a negative serum ?-human chorionic gonadotropin or urine pregnancy test at screening
DONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotrophin (HCG) test within three weeks of mobilization
Pregnancy during vaccine administration; female participants of childbearing potential must have a negative pregnancy test (serum beta human chorionic gonadotropin [B-HCG]) prior to administration of the first vaccine dose
Women who are pregnant or breastfeeding; women of child-bearing potential must have a negative pregnancy test (beta- human chorionic gonadotropin [B-HCG] test in urine or serum) prior to commencing study treatment
Negative serum beta-human chorionic gonadotropin (beta-hCG) test (women of childbearing potential only)
Women of childbearing potential must have a negative serum beta (B)-human chorionic gonadotropin (HCG) pregnancy test at initial screening and within 3 days prior to registration
Females of childbearing potential must:\r\n* Agree to using a reliable form of contraception (eg, oral contraceptives, intrauterine device, double barrier method of condom and spermicidal) for at least 28 days prior to the first dose of any study drug, during the treatment period (and treatment/follow-up if receiving study drug), and for at least 70 days after the last dose of any study drug\r\n* Have a negative serum beta-human chorionic gonadotropin (beta-HCG) at screening
Female patients of childbearing potential has a negative serum pregnancy test beta-human chorionic gonadotropin (hCG)
Woman of childbearing potential must have 2 negative highly sensitive serum (beta-human chorionic gonadotropin [b-hCG]) during screening, the first one within 10 to 14 days prior to the first dose of any component of study treatment and the second within 24 hours prior to the first dose of any component of study treatment
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential
Females of childbearing potential must have a negative beta human chorionic gonadotropin (?-hCG) pregnancy test result within 7 days prior to the first dose of study drug. Females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy.
Women of childbearing potential must have a negative urine or serum beta-human chorionic gonadotropin pregnancy test within 7 days prior to Day 1.
Female participants of childbearing potential must have 2 negative urine human chorionic gonadotropin tests within 10 to 14 days and within 24 hours prior to receiving study medication
Negative blood or urine beta-human chorionic gonadotropin (?- HCG) pregnancy test within 7 days prior to Day 1 for women of childbearing potential.
Female participants of reproductive potential must not be pregnant (negative urine or serum human chorionic gonadotropin test within 72 hours of study start)
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study; females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategies (REMS) program
Females of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test result within 7 days prior to the first dose of ibrutinib; females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy
Pregnant and/or lactating females are excluded; a negative beta-human chorionic gonadotropin [B-hCG]) is required during Screening, and a separate local assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of Test Article
Negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test at screening for patients of childbearing potential
Negative serum or urine beta-human chorionic gonadotropin (HCG) pregnancy test at screening for patients with childbearing potential
Females of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test result within 7 days prior to the first dose of SGN-35; females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy
Negative serum pregnancy test (beta human chorionic gonadotropin [beta HCG]) within 7 days of starting study, if of child-bearing potential
A woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta- hCG]) at Screening within 14 days prior to study drug administration Inclusion Criteria for Crossover:
Pregnancy or breast feeding; female patients must have a negative pregnancy test (beta-human chorionic gonadotropin [HCG] test in urine or serum) prior to commencing study treatment and must agree with the use of effective contraception during the study and for three months following last dose of nintedanib
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study
Female participants must not be pregnant (negative urine or serum human chorionic gonadotropin test within 72 hours of study start)
Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotrophin (beta-hCG) pregnancy test result within 24 hours prior to the first dose of treatment and must agree to use an effective contraception to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug; females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [Beta-hCG]) pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study; females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategy (REMS) program
Negative pregnancy test (serum beta-human chorionic gonadotropin [B-HCG]) within 7 days of starting study treatment is required in women of childbearing potential; NET patients with positive B-HCG are eligible if pregnancy can be excluded by vaginal ultrasound or lack of expected doubling of B-HCG
Women of child-bearing potential MUST have a negative serum or urine human chorionic gonadotropin (HCG) test unless prior tubal ligation (>= 1 year before screening), total hysterectomy or menopause (defined as 12 consecutive months of amenorrhea); patients should not become pregnant or breastfeed while on this study; sexually active patients must agree to use dual contraception for the duration of study participation and for 120 days after the last dose of talazoparib
Negative serum pregnancy test (beta-human chorionic gonadotropin [B-hCG]) within 72 hours before starting study treatment for all women of childbearing potential
Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within 7 days prior to treatment
DONOR: Females of childbearing potential should have a negative serum beta-human chorionic gonadotropin (HCG) test within 1 week of beginning growth factor of choice
Negative urine beta-human chorionic gonadotropin (HCG) or negative serum quantitative beta-HCG or within 2 weeks prior to registration for women of childbearing potential
Women of childbearing potential (including premenopausal women and women less than 12 months after menopause) must have a negative beta-human chorionic gonadotropin (hCG) urine pregnancy test within 4 weeks of registration
Premenopausal women of child bearing potential must have a normal urine or serum beta-human chorionic gonadotropin (HCG) prior to enrollment, and must agree to use effective contraception during treatment with nivolumab and for at least 5 months following the last dose of nivolumab
Women of childbearing potential must have a negative pregnancy test (serum or urine beta human chorionic gonadotropin [HCG]) prior to initiation of chemotherapy; both female and male breast cancer patients who are sexually active have to agree to practice contraception while participating in the trial and for 3 month after completion of therapy
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential
Females of child-bearing potential (pre-menopausal) must have a negative serum beta-human chorionic gonadotropin (HCG) pregnancy test at screening
Negative serum beta-human chorionic gonadotropin (B-hCG) pregnancy test within 72 hours of day 1 of induction chemotherapy in women of child-bearing potential
Negative serum beta-human chorionic gonadotropin (B-hCG) pregnancy test within 72 hours of day 1 of treatment with ABVD in women of child-bearing potential
Urine or serum beta-human chorionic gonadotropin (HCG) or serum HCG = negative (if female patient of childbearing potential)
Female patients with reproductive potential who do not have a negative urine or blood beta-human chorionic gonadotropin (beta HCG) pregnancy test at screening
Women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (B-HCG) pregnancy test documented within 72 hours of start of therapy
Female patient of childbearing potential must have a negative serum or urine pregnancy test (beta-human chorionic gonadotropin [hCG]) within 72 hours prior to receiving the first dose of study medication and agree to the use of effective methods of contraception while on study
Female patient of childbearing potential has a negative serum pregnancy test beta-human chorionic gonadotropin (b-hCG) within 7 days prior to receiving the first dose of vorinostat
Female patients of childbearing potential (WOCBP) must have a negative serum pregnancy test beta-human chorionic gonadotropin (hCG) within 7 days of the first treatment
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of child-bearing potential (this is routinely done if the patient is premenopausal and having surgery)
Negative serum beta human chorionic gonadotropin (?hCG) test (for women of childbearing potential only)
Patients of childbearing potential must agree to use some form of adequate birth control during the periods they receive chemotherapy and any post-chemotherapy medications related to the transplant; females of child bearing potential must have a negative serum beta-human chorionic gonadotropin (B-HCG) within 1 week of starting therapy
DONOR: Females of childbearing potential should have a negative serum beta-human chorionic gonadotropin (HCG) test within 1 week of beginning G-CSF mobilization
Females must not be pregnant (negative human chorionic gonadotropin test within 72 hours prior to receiving the first dose of study medication) or breastfeeding
Female participants must not be pregnant (negative urine or serum human chorionic gonadotropin test at screening and again within 72 hours prior to receiving the first dose of study therapy)
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [B-hCG]) or urine pregnancy test at screening
Females of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) pregnancy test at screening; pregnancy testing is not required for: (a) women who have been post-menopausal for at least 2 years without menses; or (b) women who are surgically sterile (e.g. by means of hysterectomy, tubal ligation, etc.)
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening within 7 days of enrollment
Females must not be pregnant (negative urine or serum human chorionic gonadotropin test within 72 hours of study start)
Negative serum beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only), to be performed locally within the screening period
Negative beta human chorionic gonadotropin (bHCG) within 14 days prior to study entry if patient is pre or perimenopausal
Negative pregnancy test (beta human chorionic gonadotropin [HCG]) within 14 days of study drug initiation for pre- or perimenopausal subjects with an intact uterus
Negative serum beta-human chorionic gonadotropin (B-HCG) test (female patient of childbearing potential only) performed locally within 72 hrs prior to first dose
If a female patient is of childbearing potential, she must have a negative serum pregnancy test (beta-human chorionic gonadotropin [hCG]) documented within 72 hours of the first administration of study drug
Male or non-pregnant and non-lactating female; if a female patient is of childbearing potential, she must have a negative serum pregnancy test (beta-human chorionic gonadotropin [b-hCG]) documented within 72 hours of the first administration of study drug
Negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test at screening for patients of childbearing potential
A woman of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening
Have a negative pregnancy test Beta Human Chorionic Gonaditrophin(ß-hCG) as verified by the study doctor within 72 hours prior to starting study therapy.
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test within 14 days of day (D)1 of neoadjuvant chemotherapy for women of childbearing potential
If female patient is of child bearing potential, she must have a negative serum pregnancy test (beta human chorionic gonadotropin [hCG]) documented up to 72 hours (hrs) prior to administration of first study drug
Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within 14 days prior to the first dose of brentuximab vedotin and must agree to use an effective contraception method during the study and for 30 days following the last dose of study drug; females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy
Negative serum beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) performed locally within 72 hours (hrs) prior to first dose
Negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test at screening, performed no more than 72 hours prior to treatment initiation; for women of childbearing potential
A positive urine and/or serum beta-human Chorionic Gonadotropin pregnancy test
Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within 14 days prior to registration
Patients of childbearing potential must have a negative serum or urine pregnancy test (beta human chorionic gonadotropin) within 72 hours prior to receiving the first dose of study treatment.
Female patients of childbearing potential must have a negative serum pregnancy test (human chorionic gonadotropin beta subunit [B-hCG] pregnancy test) within 72 hours prior to receiving the first dose of vorinostat; male patients enrolled in this study should also agree to use an adequate method of contraception for the duration of the study
DONOR: Females of childbearing potential should have a negative serum beta-human chorionic gonadotropin (HCG) test within 1 week of beginning apheresis
Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only)
Negative beta human chorionic gonadotropin (HCG) in woman with child-bearing potential
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [b-hCG]) or urine pregnancy test within 7 days prior to treatment initiation and when clinically indicated every 4 weeks +/- 7 days while receiving study drugs, as shown in study calendar; women who are pregnant or breastfeeding are ineligible for this study
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential
Within 4 weeks of therapy start, women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening and must adhere to the scheduled pregnancy testing
Negative serum beta (?) human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within 72 hours prior to first dose
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential
Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within 21 days prior to registration
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study
A female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum beta-human chorionic gonadotrophin [beta-hCG] test) in females of reproductive potential), not lactating or if of reproductive potential agrees to follow one of the options listed in protocol from 30 days prior to the first dose of study medication and until 120 days after the last dose of study treatment.
Negative beta-human chorionic gonadotropin (betaHCG) pregnancy test among females of childbearing age
Pregnancy or breast feeding; female patients with child-bearing potential must have a negative pregnancy test (beta-human chorionic gonadotropin [B-HCG] test in urine or serum) prior to commencing study treatment
If a female of child-bearing potential, must not be pregnant or planning to become pregnant during the study\r\n* Women < 50 years old must have a negative pregnancy test (urine human chorionic gonadotropin [HCG] or serum betaHCG) within 2 weeks of beginning chemotherapy
Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration
Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration
Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration
DONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test within three weeks of apheresis
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential
Women of childbearing age will be required to have a negative human chorionic gonadotropic (HCG) test within seven days of surgery
Female subjects capable of reproduction must have a negative beta human chorionic gonadotropin (BHCG) serum or urine pregnancy test result within 7 days prior to first Investigational Product dose
Negative pregnancy test (females of child bearing potential) within =< 1 week of rasburicase dose and use of efficient contraceptive method (both males and females); pregnancy test may be performed on serum (human chorionic gonadotropin [HCG]) or urine (HCG)
RECIPIENT: Negative serum or urine beta?human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration
Females of childbearing potential are to agree to practice a medically acceptable contraceptive regimen (including a barrier method) from study treatment initiation until at least 30 days after the last administration of Folotyn or leucovorin, whichever is last, and are to have a negative urine beta human chorionic gonadotropin (?-HCG) pregnancy test within 14 days prior to the first day of study treatment. Females who are postmenopausal for at least 1 year (defined as >12 months since last menses) or are surgically sterilized do not require this test
Women of child-bearing potential must also have a negative urine pregnancy test (beta-human chorionic gonadotropin [HCG]) within 72 hours of receiving treatment
Pregnant or lactating patients will be excluded, as will females of childbearing potential who refuse to undergo a serum or urinary beta-human chorionic gonadotropin (HCG) pregnancy test the day of either the 18F-FSPG or the 18F-FDG PET/CT scans in accordance with the standard policy of the Medical Imaging Service at our facility; women who have experienced 24 consecutive months of amenorrhea, have reached at least 60 years of age, or have had a tubal ligation or hysterectomy documented in their medical records are considered not to be of childbearing potential for the purposes of this protocol
Negative serum beta-human chorionic gonadotropin (beta-hCG) test (women of childbearing potential only)
Women of childbearing potential, unless they have had a negative urine beta human chorionic gonadotropin (betaHCG) within the previous 24 hours of the procedure
All post-menarchal females must have a negative beta-human chorionic gonadotropin (HCG) within 2 weeks prior to receiving the dose of 124I-MIBG; males and females of childbearing potential must practice an effective method of birth control while participating on this study, to avoid possible damage to the fetus
Women of childbearing potential, unless they have had a negative urine human chorionic gonadotropin (HCG) within the previous 24 hours of the procedure
Negative serum ? -HCG (beta human chorionic gonadotropin) test for female of child bearing potential at screening and a negative urine pregnancy test at Day 1.
Subjects who are pregnant or nursing; urine pregnancy test/or serum human chorionic gonadotropin (HCG) will be performed on women of child bearing potential
Women of childbearing potential must have a negative beta-human chorionic gonadotropin pregnancy test documented within 7 days prior to treatment. Have given written informed consent prior to any study-specific procedures.
Negative urine or serum beta-human chorionic gonadotropin (?-HCG) pregnancy test within 7 days prior to the Cycle 1, Day 1 visit, for women of childbearing potential.
